Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
Latest From Market Access
In case you missed it: catch up with snippets from interviews recently published by In Vivo.
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
Hearing direct from HTA agencies on what evidence they want to see is now an option through early dialogue. With many options for early dialogue available, it is hard for companies to know whether to get advice, from which agency and how to get the most out of the dialogue.
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
A new digital ecosphere to support the efficient delivery of individualized cancer therapies to patients has been released by data and information management company EY. It is an open source framework that can be accessed by all stakeholders in the care delivery chain.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.